Clinical Trial Update: Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of F16IL2 with paclitaxel in solid tumors, including breast cancer, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Solid Tumor

Drugs mentioned

• F16IL2 (F16-IL2)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Philogen S.p.A. | Conditions: Solid Tumor, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED